Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$44.36 USD
-0.18 (-0.40%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $44.38 +0.02 (0.05%) 7:36 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Income Statements
Fiscal Year end for Amphastar Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 644 | 499 | 438 | 350 | 322 |
Cost Of Goods | 293 | 250 | 238 | 207 | 190 |
Gross Profit | 351 | 249 | 200 | 143 | 132 |
Selling & Adminstrative & Depr. & Amort Expenses | 154 | 141 | 130 | 132 | 132 |
Income After Depreciation & Amortization | 197 | 108 | 70 | 11 | 0 |
Non-Operating Income | 2 | 10 | 15 | -6 | 60 |
Interest Expense | 27 | 2 | 1 | 0 | 0 |
Pretax Income | 171 | 116 | 84 | 5 | 60 |
Income Taxes | 32 | 23 | 21 | 4 | 14 |
Minority Interest | 0 | 0 | 1 | 0 | -2 |
Investment Gains/Losses | -2 | -1 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 138 | 91 | 63 | 1 | 47 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 138 | 91 | 62 | 1 | 49 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 246 | 133 | 93 | 32 | 18 |
Depreciation & Amortization (Cash Flow) | 49 | 25 | 23 | 22 | 18 |
Income After Depreciation & Amortization | 197 | 108 | 70 | 11 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 53.00 | 52.43 | 49.78 | 49.12 | 49.91 |
Diluted EPS Before Non-Recurring Items | 3.02 | 1.70 | 1.37 | 0.64 | 0.36 |
Diluted Net EPS (GAAP) | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 |
Fiscal Year end for Amphastar Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 182.39 | 171.84 | 178.11 | 180.56 | 145.71 |
Cost Of Goods | 87.23 | 81.74 | 81.96 | 72.15 | 72.97 |
Gross Profit | 95.17 | 90.10 | 96.14 | 108.40 | 72.74 |
SG&A, R&D, and Dept/Amort Expenses | 39.95 | 42.09 | 42.16 | 35.72 | 35.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 55.22 | 48.01 | 53.98 | 72.68 | 36.90 |
Non-Operating Income | 3.64 | 8.48 | -3.18 | 4.66 | -0.49 |
Interest Expense | 8.61 | 8.61 | 9.46 | 13.70 | 3.60 |
Pretax Income | 50.24 | 47.88 | 41.34 | 63.64 | 32.81 |
Income Taxes | 12.29 | 4.13 | 4.67 | 14.03 | 6.38 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | -0.57 | -0.50 | -0.39 | -0.30 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 37.95 | 43.18 | 36.17 | 49.22 | 26.12 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 37.95 | 43.18 | 36.17 | 49.22 | 26.12 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 52.05 | 53.01 | 53.01 | 53.92 | 53.10 |
Diluted EPS Before Non-Recurring Items | 0.85 | 0.93 | 0.81 | 1.08 | 0.58 |
Diluted Net EPS (GAAP) | 0.73 | 0.81 | 0.70 | 0.91 | 0.49 |